CR Sanjiu will distribute over 1.7 billion in cash in 2025, highlighting a high dividend payout that underscores its dividend characteristics同壁财经·May 28 at 08:37 PM000999-1.57%
New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to ChangeWallstreetcn·Apr 14 at 07:17 AM01666-1.01%005700.00%
China Resources Pharmaceutical's subsidiary CR Sanjiu's annual net profit increased by 1.6% to 3.421 billion RMBAASTOCKS·Mar 22 at 08:35 PM159316+1.20%159929+1.75%
CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%AASTOCKS·Feb 8 at 04:56 AM000999-1.57%03320-0.10%
CR Sanjiu's registered capital increased to approximately 1.66 billion yuan36Kr·Feb 4 at 10:42 PM000999-1.57%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27 at 04:41 AM512290+2.71%159929+1.75%
CR Sanjiu: CHINARES PHARMA's pediatric tranquilizer and brain supplement granules have received implied approval for clinical trialsAASTOCKS·Nov 18, 2025 at 10:25 PM000999-1.57%03320-0.10%
The morning session of the 2025 National Conference opens: CR Sanjiu and YILING PHARMACEUTICAL enter the arena, negotiations on traditional Chinese medicine varieties beginZhitong·Nov 1, 2025 at 07:59 PM002603+0.42%000999-1.57%
China Resources Pharmaceutical's subsidiary CR Sanjiu earned 2.899 billion yuan in the first three quarters, a decline of 10.6%AASTOCKS·Oct 26, 2025 at 05:16 AM000999-1.57%
